CTOs on the Move

Capcium

www.capcium.com

 
Capcium is a value-add pharmaceutical grade manufacturer of softgel capsules and other novel delivery technologies that was born from a strong desire to transform the cannabis, pharmaceutical, nutraceutical, over the counter (OTC) and cosmetics industries by setting new standards in the development and manufacturing of finished consumer products.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.capcium.com
  • 1675 Rte Transcanadienne Suite 135
    Dorval, QC CAN H9P 1J1
  • Phone: 514.339.5986

Executives

Name Title Contact Details

Similar Companies

Mankind Pharma

Mankind Pharma is one of the Indian leading pharmaceutical companies, and changes the pharma industry by providing world class medications at affordable prices and maintaining quality standards by using state-of-the-art technology for production of hig...

Napp Technologies

Napp Technologies is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DSM Pharmaceutical Products

DSM is active worldwide in life science products, performance materials and industrial chemicals. The group has annual sales of close to EUR 5.6 billion and employs about 18,500 people at more than 200 sites across the world. DSM ranks among the global

Elevation Pharmaceuticals

Elevation Pharmaceuticals is a biopharmaceutical company focused on developing new inhaled therapies for patients with respiratory disease.

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.